Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23826972 | 1.00 | USP2 (0.42) | USP2SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL23826974 | 1.00 | USP2 (0.42) | USP2SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL28624038 | 1.00 | USP2 (0.42) | USP2SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL28804351 | 0.79 | USP2 (0.39) | USP2SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL28804350 | 0.79 | USP2 (0.39) | USP2SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL29715682 | 0.79 | USP2 (0.39) | USP2SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL12174992 | 0.79 | USP2 (0.51) | USP2SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL20571388 | 0.78 | USP2 (0.40) | USP2SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL20571390 | 0.78 | USP2 (0.40) | USP2SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL20571387 | 0.78 | USP2 (0.40) | USP2SMN1; SMN2ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-13 | — | — | US | disclosed |
| US-11466017-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3463343-B1 | HETEROCYCLIC INHIBITORS OF PTPN11 | UNIV TEXAS (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466017-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | USP2 1045/4885SMN1; SMN2 4183/4885ALDH1A1 2947/4885 |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | USP2 1045/4885SMN1; SMN2 4183/4885ALDH1A1 2947/4885 |
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | USP2 1009/4885SMN1; SMN2 4080/4885ALDH1A1 3201/4885 |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | USP2 1045/4885SMN1; SMN2 4183/4885ALDH1A1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.